Sign in
  1. Home
  2. Companies
  3. Align Technology
  4. Financial Ratios
Align Technology logo
Align Technology ALGN
$ 148.17 4.36%
report update icon

Quarterly report 2026-Q2
added 08-05-2026

Align Technology Financial Ratios 2025-2007 | ALGN

Brief overview of Align Technology's market valuation

The comparison uses the five latest available annual observations between 2021 and 2025.

The current valuation set is P/E 31.58x (median 52x), EV/EBITDA 17.93x (median 31.38x), P/S 3.21x (median 5.99x). Multiples are on average 42.9% below their own medians. Shares look cheaper than their recent historical valuation.

At the current P/E, inverse earnings yield is 3.2%, a useful bridge between price and business earnings.

The latest available business-quality ratios are ROE 10.1%, ROA 6.6%, ROCE 13.5%. Capital returns look adequate and support overall financial resilience.

Current PEG of 1.48x shows no clear imbalance between price and expected earnings momentum.

A longer cycle, from 83.2 days to 129.4 days, indicates slower release of cash from operations.

Overall assessment

Align Technology's multiples are below five-year reference levels despite strong quality metrics, providing valuation cushion but not eliminating hidden risks.

Annual Financial Ratios Align Technology

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

P/E

 31.6 33.1 52.0 66.0 67.2 23.7 47.2 46.6 93.5 37.9 36.7 29.4 73.3 40.2 29.7 14.7 -27.7 10.9 -

P/S

 3.2 3.5 6.0 6.4 13.1 17.0 8.7 9.5 14.7 6.7 6.3 5.6 7.1 4.2 4.1 2.8 2.8 2.9 -

EPS

 5.7 5.6 5.8 4.6 9.8 22.6 5.6 5 2.9 2.4 1.8 1.8 0.8 0.7 0.9 1.0 -0.5 1.2 -

EV (Enterprise Value)

 14 B 15.2 B 24.7 B 25.3 B 53.1 B 42.7 B 21.5 B 18.8 B 21.8 B 7.2 B 5.43 B 4.32 B 4.67 B 2.23 B 1.9 B 895 M 783 M 785 M -89.1 M

EBITDA per Share

 10.8 10.1 10.3 9.83 13.8 6.1 7.47 6.51 4.89 3.42 2.58 2.62 2.21 1.56 1.19 1.51 -0.34 0.38 -

EV/EBITDA

 17.9 20.3 31.4 32.9 48.9 84.1 34.3 34.5 54.1 24.9 24.8 19.3 25.1 16.3 18.7 7.8 -32.9 30.8 -

PEG

 1.48 2.05 2.66 2.61 1.7 1.13 4.14 0.64 4.36 1.18 -66.5 0.23 7.64 -2.66 -2.42 - - - -

P/B

 3.2 3.6 6.4 6.6 14.3 13.0 15.5 14.9 18.8 7.2 6.2 5.7 7.4 4.1 4.0 2.9 3.2 - -

P/CF

 21.8 18.9 29.4 42.0 44.2 63.6 34.9 56.3 89.1 40.6 28.7 21.1 28.3 24.7 19.8 8.4 11.7 22.0 -

ROE %

 10.13 10.93 12.26 10.05 21.31 54.92 32.89 31.94 20.12 19.06 16.98 19.37 10.14 10.10 13.59 19.66 -8.28 36.60 -

ROA %

 6.58 6.77 7.31 6.09 12.99 36.77 17.71 19.50 13.02 13.59 12.43 14.76 7.73 7.76 10.28 15.57 -8.80 - -

ROCE %

 13.48 15.77 17.72 17.84 26.95 11.97 33.63 34.30 27.62 23.89 21.27 24.62 24.55 20.35 18.03 27.20 -9.00 7.10 -

Current Ratio

 2.9 2.6 2.5 2.5 2.6 3.0 1.7 1.9 2.3 2.7 2.7 3.3 3.1 3.1 2.6 4.8 4.3 - -

DSO

 94.9 86.7 83.3 85.9 71.8 89.2 94.2 81.5 80.0 83.6 68.4 62.2 62.6 64.5 69.6 56.6 31.9 - -

DIO

 66.3 83.8 100.4 94.3 66.3 64.7 61.7 39.2 32.4 37.4 34.6 31.7 31.5 38.4 29.0 10.0 4.7 - -

DPO

 31.7 33.7 38.1 48.4 54.9 59.1 48.0 45.2 37.7 39.4 85.6 57.7 46.1 57.0 68.8 30.3 14.2 - -

Operating Cycle

 161.1 170.5 183.7 180.2 138.1 153.9 155.9 120.6 112.4 121.1 103.0 93.9 94.1 102.9 98.6 66.6 36.6 - -

Cash Conversion Cycle

 129.4 136.8 145.7 131.8 83.2 94.8 107.8 75.4 74.8 81.6 17.4 36.2 47.9 46.0 29.9 36.3 22.4 - -

All numbers in USD currency

Quarterly Financial Ratios Align Technology

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q3 2010-Q2

EPS

 1.51 1.58 0.78 1.72 1.27 - 1.55 1.28 1.4 - 1.59 1.46 1.14 - 0.93 1.44 1.71 - 2.29 2.53 2.54 - 1.77 -0.52 19.32 - 1.29 1.84 0.9 - 1.26 1.32 1.2 - 1.03 0.86 0.87 - 0.64 0.63 0.51 - 0.35 0.39 0.45 - 0.47 0.44 0.4 - 0.43 0.36 -0.52 - - 0.35 0.26 - 0.25 0.14 0.21 0.22 0.43

EBITDA per Share

 2.72 2.78 2.1 2.81 2.31 - 2.68 2.44 2.49 - 2.66 2.71 2.2 - 2.25 2.79 2.89 - 3.66 3.73 3.18 - 2.56 -0.63 1.15 - 1.85 2.45 1.33 - 1.74 1.69 1.37 - 1.36 1.15 0.87 - 0.86 0.88 0.73 - 0.64 0.63 0.66 - 0.81 0.71 0.57 - 0.68 0.58 -0.41 - 0.21 0.52 0.39 - 0.45 0.29 0.31 0.4 0.68

ROE %

 9.90 9.79 10.02 11.15 10.76 8.30 11.50 11.63 11.58 8.79 10.76 10.70 11.29 8.76 13.91 17.84 20.61 16.95 21.26 14.86 55.90 50.00 57.61 64.24 70.83 23.88 31.93 32.79 29.51 24.17 31.32 29.27 26.81 19.16 24.32 22.21 20.29 14.27 17.53 16.07 15.29 11.22 16.30 17.77 18.39 14.12 19.57 19.11 7.76 3.45 3.39 2.84 1.83 8.45 12.38 14.71 13.04 9.43 14.11 19.94 3.23 4.68 9.76

ROA %

 6.39 6.23 6.26 6.92 6.62 5.10 7.02 7.02 6.94 5.23 6.46 6.80 8.18 6.69 10.39 9.16 13.12 10.86 13.74 9.70 37.43 33.48 37.58 40.58 44.29 12.86 17.77 18.84 17.63 14.76 19.38 18.35 17.07 12.40 16.08 15.04 14.07 10.18 12.56 11.59 11.12 8.21 12.08 13.30 13.88 10.76 14.91 14.56 5.91 2.63 2.58 2.20 1.45 6.50 9.46 11.23 9.90 7.13 10.90 15.91 2.44 3.78 7.98

ROCE %

 13.66 13.48 14.17 15.65 15.58 12.13 16.50 17.11 17.04 12.94 16.83 17.68 18.36 14.52 21.95 26.00 27.42 22.01 27.49 17.81 12.02 5.38 14.83 22.46 31.23 29.07 39.06 39.41 34.14 27.62 36.18 33.43 28.98 21.14 27.38 25.36 23.48 18.14 22.63 21.38 20.61 15.25 22.10 24.08 24.64 18.87 25.42 24.55 12.07 6.51 7.29 6.94 5.78 11.79 17.15 19.76 17.84 13.03 19.13 27.34 4.28 6.10 13.58

Current Ratio

 2.9 2.9 2.7 2.7 2.6 2.6 2.6 2.6 2.6 2.5 2.5 2.5 2.4 2.5 2.7 - 2.6 2.6 2.6 2.7 3.0 3.0 3.0 3.0 3.0 2.2 2.2 2.2 2.2 2.6 2.6 2.6 2.6 2.8 2.8 2.8 2.8 3.5 3.5 3.5 3.5 3.7 3.7 3.7 3.7 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.3 4.3 4.3 4.3 4.1 4.1 4.1 4.1 5.2 5.5

DSO

 98.2 97.6 101.5 98.2 95.9 - 94.8 87.4 84.8 - 86.1 81.6 84.4 - 44.0 44.8 86.6 - 74.7 68.9 70.2 - 81.8 170.3 27751.7 - 14437.6 14491.8 17142.7 - 17931.8 20897.0 16002.3 - 16200.6 20529.0 21823.8 - 81.0 83.8 77.6 - 69.7 69.1 66.4 - 62.4 61.5 61.4 - 62.8 63.1 63.0 - 66.2 62.0 64.3 - 66.3 69.6 67.6 60.3 -

DIO

 65.2 66.6 60.4 73.5 76.4 - 79.1 80.5 87.9 - 93.5 98.8 105.1 - 54.0 44.6 87.5 - 67.5 59.6 60.8 - 63.5 99.3 73.2 - 60.2 60.7 52.1 - 38.0 40.7 36.4 - 31.2 33.8 35.9 - 35.7 38.6 36.6 - 35.5 34.9 34.4 - 32.4 30.9 31.4 - 32.3 31.8 32.6 - 38.2 37.5 32.6 - 25.6 29.6 23.8 10.6 -

DPO

 35.7 37.5 30.7 36.0 35.7 - 33.1 33.3 35.1 - 32.2 38.1 41.7 - 23.4 30.2 60.6 - 70.0 63.2 55.8 - 64.8 101.3 66.8 - 46.9 47.3 47.1 - 43.9 47.0 42.1 - 36.2 39.2 39.9 - 37.6 40.7 49.4 - 62.6 61.6 55.9 - 47.3 45.1 43.1 - 41.0 40.3 41.7 - 49.4 48.4 51.6 - 52.4 60.7 50.6 24.2 -

Operating Cycle

 - - 161.9 171.7 172.3 - 173.9 167.9 172.7 - 179.6 180.4 189.4 - 98.0 89.3 174.1 - 142.2 128.5 131.0 - 145.3 269.6 27824.9 - 14497.8 14552.5 17194.8 - 17969.8 20937.7 16038.6 - 16231.7 20562.8 21859.7 - 116.7 122.4 114.2 - 105.2 104.0 100.8 - 94.8 92.4 92.8 - 95.2 94.8 95.6 - 104.4 99.5 97.0 - 91.9 99.2 - - -

Cash Conversion Cycle

 - - 131.2 135.7 136.6 - 140.8 134.7 137.6 - 147.4 142.3 147.7 - 74.7 59.2 113.5 - 72.2 65.3 75.1 - 80.4 168.3 27758.0 - 14451.0 14505.2 17147.8 - 17925.9 20890.7 15996.5 - 16195.6 20523.5 21819.8 - 79.1 81.7 64.8 - 42.5 42.4 44.8 - 47.5 47.3 49.7 - 54.1 54.6 53.9 - 55.0 51.1 45.4 - 39.5 38.5 - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Align Technology, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
AxoGen AxoGen
AXGN
 		$ 43.32 0.04 % $ 1.99 B usaUSA
Bruker Corporation Bruker Corporation
BRKR
 		$ 59.67 0.18 % $ 9.06 B usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
 		$ 8.73 1.16 % $ 637 M israelIsrael
ClearPoint Neuro ClearPoint Neuro
CLPT
 		$ 14.97 13.03 % $ 424 M usaUSA
Conformis Conformis
CFMS
 		- - $ 16.4 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
 		$ 45.8 3.31 % $ 1.42 B usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
 		$ 4.91 0.75 % $ 306 M usaUSA
Delcath Systems Delcath Systems
DCTH
 		$ 15.96 1.8 % $ 572 M usaUSA
Eargo Eargo
EAR
 		- - $ 10.2 M usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
 		$ 5.7 0.43 % $ 770 M usaUSA
Electromed Electromed
ELMD
 		$ 27.57 0.11 % $ 228 M usaUSA
Establishment Labs Holdings Establishment Labs Holdings
ESTA
 		$ 67.76 3.69 % $ 2.01 B costa-ricaCosta-rica
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
 		$ 86.82 0.51 % $ 50.8 B usaUSA
Helius Medical Technologies Helius Medical Technologies
HSDT
 		$ 2.88 2.45 % $ 63.5 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
 		$ 15.53 2.76 % $ 1.19 B usaUSA
Inogen Inogen
INGN
 		$ 5.09 2.55 % $ 135 M usaUSA
Inspire Medical Systems Inspire Medical Systems
INSP
 		$ 69.06 0.57 % $ 2.03 B usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
 		$ 0.63 0.08 % $ 10.7 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
 		$ 86.35 0.08 % $ 1.1 B usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
 		$ 126.32 0.02 % $ 4.39 B usaUSA
LENSAR LENSAR
LNSR
 		$ 7.15 0.14 % $ 85.5 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
 		- 10.28 % $ 55.5 M israelIsrael
Apyx Medical Corporation Apyx Medical Corporation
APYX
 		$ 2.95 1.37 % $ 121 M usaUSA
Cutera Cutera
CUTR
 		- -10.19 % $ 1.99 M usaUSA
Medtronic PLC Medtronic PLC
MDT
 		$ 89.3 0.08 % $ 114 B usaUSA
MiMedx Group MiMedx Group
MDXG
 		$ 4.77 0.2 % $ 705 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
 		$ 0.23 1.0 % $ 28.2 M usaUSA
Myomo Myomo
MYO
 		$ 1.64 0.3 % $ 68.6 M usaUSA
Nano-X Imaging Ltd. Nano-X Imaging Ltd.
NNOX
 		$ 0.7 0.45 % $ 45.4 M israelIsrael
Nemaura Medical Nemaura Medical
NMRD
 		- -17.8 % $ 2.74 M britainBritain
InspireMD InspireMD
NSPR
 		$ 0.74 0.16 % $ 47.6 M israelIsrael
Orthofix Medical Orthofix Medical
OFIX
 		$ 9.18 2.23 % $ 364 M curacaoCuracao
Outset Medical Outset Medical
OM
 		$ 3.09 5.45 % $ 47 K usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
 		$ 44.62 0.31 % $ 66.1 B usaUSA
Insulet Corporation Insulet Corporation
PODD
 		$ 136.49 0.01 % $ 9.6 B usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
 		$ 5.74 0.16 % $ 174 M canadaCanada
Quanterix Corporation Quanterix Corporation
QTRX
 		$ 3.16 4.93 % $ 135 M usaUSA
AVITA Medical AVITA Medical
RCEL
 		$ 10.95 0.61 % $ 305 M australiaAustralia
Neovasc Neovasc
NVCN
 		- - $ 111 M canadaCanada
Sintx Technologies Sintx Technologies
SINT
 		$ 1.78 3.98 % $ 4.94 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
 		$ 26.82 0.07 % $ 23.3 B britainBritain
Inari Medical Inari Medical
NARI
 		- - $ 4.23 B usaUSA
Sensus Healthcare Sensus Healthcare
SRTS
 		$ 3.03 0.32 % $ 49.5 M usaUSA
Stryker Corporation Stryker Corporation
SYK
 		$ 273.4 0.38 % $ 104 B usaUSA
Tactile Systems Technology Tactile Systems Technology
TCMD
 		$ 22.43 0.55 % $ 513 M usaUSA
TELA Bio TELA Bio
TELA
 		$ 1.3 0.71 % $ 61 M usaUSA
Viemed Healthcare Viemed Healthcare
VMD
 		$ 8.8 1.24 % $ 342 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
 		$ 18.45 0.05 % $ 764 M usaUSA
Sientra Sientra
SIEN
 		- -16.59 % $ 10.3 M usaUSA